

Ovarian Cancer: Effective Practices to Benefit Patients

- In advanced ovarian cancer, genetic testing rates hover around 50%.¹
- Only 49% of patients received maintenance therapy in second line or greater therapy.²
- Current rates warrant improved methods and practices to enable professionals to both identify and offer PARP-Inhibitors to appropriate patients at the right time.
 - **NCODA's Positive Quality Intervention (PQI)** on this topic provides practical guidance and is available here: www.ncoda.org/ovarian-cancer-parp-inhibitor-eligibility

This EMR Resource provides simple step-by-step instructions to:

 **1. Run a Report:** to search for all ovarian cancer patients

 **2. Review Chart:** to conduct a clinical assessment

 **3. Create Reminders and Track:** key treatment milestones and timing of therapy

1. Run a Report

To identify all ovarian cancer patients within the EMR, search by "Ovarian"

* If you do not have access to this reporting function, work with your Information Technology (IT) team or iKnowMed support directly

Login to **Reporting Center** dashboard*

Select **Patients by Diagnosis**

Select **All Locations**

Time frame set to **One Year** (can adjust)

Select **Disease State/Group: Ovarian**

Select **View Report**

2. Review Chart

From the patient list, select a patient and review each patient case to determine

Genetics / mutational status (BRCA and other HRD)

- | | | | | | |
|----------|---|----------|-----------------------------------|----------|--|
| 1 | Select Pathology / Reports in vertical toolbar | 2 | Select report for genomic testing | 3 | Alternatively, select Chart → Show Recent Attachments → Pathology Reports |
|----------|---|----------|-----------------------------------|----------|--|



Current treatment and disease stage (primary, in response, recurrence)

- | | | | | | |
|----------|---|----------|------------------------------|----------|--------|
| 1 | Select Date of recent office visit | 2 | Select Progress Notes | 3 | Assess |
|----------|---|----------|------------------------------|----------|--------|



Eligibility for PARP-I

Discuss findings with provider including the need for genetic testing if not done, and begin prescription creation process when appropriate

3. Create Reminders and Track

For each patient, create a tracking system and reminder flag via “To Do List” function, or, utilize a Calendar reminder system

For iKnowMed G2 users:

- | | | | | | |
|----------|------------------------------|----------|---|----------|--|
| 1 | Select Chart Messages | 2 | Select Recipient -> select yourself | 3 | Name the Reminder subject and include Date (ie. Review Genomics 11/1/2021) |
|----------|------------------------------|----------|---|----------|--|



Send the Chart Message

for each of the three **intervention points** listed below

For iKnowMed G1 users:

Create **Outlook Calendar reminder** (HIPAA compliant) to review genetics and treatment options for each of the following **intervention points**:

- | | | | | | |
|----------|---|----------|---|----------|---|
| 1 | At the end of Cycle 5 of initial chemotherapy (if not already done) | 2 | Within 3 months of the end of initial chemotherapy (if in response) | 3 | If recurrent disease and not in treatment, schedule appointment with provider to evaluate |
|----------|---|----------|---|----------|---|

1. Randall LM, Aydin E, Louie-Gao M, Hazard S, Westin SN. A retrospective analysis of real-world tumor BRCA (tBRCA) testing trends in ovarian cancer before and after PARP inhibitor approvals. Presented at the 17th Biennial Meeting of the International Gynecologic Cancer Society; Kyoto, Japan: 2018.
2. Garofalo D, Verma-Kurvari S, Aydin E, et al. Real world data analysis of ovarian cancer maintenance utilization among maintenance eligible patients. Presented at the American Society of Clinical Oncology Annual Congress; Chicago, IL: 2019.

